Abivax (NASDAQ:ABVX) shares fell sharply on Tuesday after investors focused on reports of rare malignancy cases in a ...

Analysts have described the experimental drug as a potential best-in-class treatment for ulcerative colitis. Abivax is also ...

Abivax (ABVX) plunged in premarket trading on Tuesday despite announcing positive Phase 3 maintenance trial results for its ...

Shares in French biotech Abivax tumbled more than 30% today, after it announced phase 3 data with ulcerative colitis (UC) ...

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative ColitisAt ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

June 1 (Reuters) - Abivax said on Monday its experimental drug for patients with ulcerative colitis, a type of chronic inflammatory ​disease, met the main goal of a closely watched late-stage trial.

Abivax has raised the efficacy bar in ulcerative colitis, linking obefazimod to a 40%, placebo-adjusted jump in clinical remission rates in a phase 3 trial. But the share price of the biotech, a ...

For some people, relief can last years. For others, only a few weeks. Learn what to do to stay in remission for as long as possible.

Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD). It causes painful sores and inflammation deep inside your colon and rectum. That can lead to hard-to-manage symptoms like ...

While some studies suggest CBD oil may help reduce inflammation and provide symptomatic relief for ulcerative colitis, more research is needed to confirm its effectiveness. The FDA has not approved ...

Next up video playing in 10 seconds Which Tests Check for Ulcerative Colitis Remission? Alan Moss, MD, chief scientific officer of the Crohns & Colitis Foundation, defines the typ ...